A Phase I Trial of Escalating Doses of Cixutumumab (IMC- A12) and Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma

PURPOSE: The insulin-like growth factor (IGF) pathway is activated in hepatocarcinogenesis. Cixutumumab is a monoclonal antibody against human insulin-like growth factor-1 receptor (IGF-1R). Given the cross-talk between the IGF and VEGF pathways, we performed a phase I study of the combination of ci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: El-Khoueiry, Anthony B., O’Donnell, Robert, Semrad, Thomas J., Mack, Philip, Blanchard, Suzette, Bahary, Nathan, Jiang, Yixing, Yen, Yun, Wright, John, Chen, Helen, Lenz, Heinz-Josef, Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6330274/
https://ncbi.nlm.nih.gov/pubmed/29520435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3553-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados